Forte Biosciences is in a high-risk, capital-intensive transition, having pivoted from the failed FB-401 program to the FB-102 asset, which is driving a sharp increase in R&D expenses and operating losses. The company's investment thesis is entirely dependent ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.97+10.2% vs -$1.08 | — vs — |
Q2 2026 May 21, 2026 | -$1.24-6.9% vs -$1.16 | — vs — |
Q2 2026 Mar 31, 2026 | -$1.45-2.1% vs -$1.42 | — vs — |
Q4 2025 Nov 14, 2025 | -$0.99+4.8% vs -$1.04 | — vs — |
Squarepoint Ops LLC trimmed its holdings in Forte Biosciences, Inc. (NASDAQ: FBRX) by 40.7% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 12,317 shares of the company's stock after selling 8,438 shares during the quarter. Squarepoint Ops LLC owned about 0.06% of Forte Biosciences
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx's portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases.
Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 12, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Benchmark FBRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Forte Biosciences, Inc. (FBRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $76.99 | $1.83B | -16.35 | — | — | -122.28% | — | |
| $50.00 | $1.37B | -294.12 | 104.94% | 12.02% | 40.13% | — | |
| $252.96 | $7.05B | -18.77 | -100% | — | -34.15% | — | |
| $5.92 | $582.82M | -2.97 | — | — | -72.28% | — | |
| $68.17 | $2.93B | -42.87 | 146.71% | -7.67% | -13.53% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — |
Forte Biosciences, Inc. (FBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Forte Biosciences, Inc. (FBRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 27, 2026·SEC
Jul 27, 2026·SEC
Jul 9, 2026·SEC
Get notified when FBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Forte Biosciences, Inc. (FBRX) stock FAQ — growth, dividends, profitability & financials explained
Forte Biosciences, Inc. (FBRX) reported a net loss of $87.9M for fiscal year 2025.
Forte Biosciences, Inc. (FBRX) has a return on equity (ROE) of -122.3%. Negative ROE indicates the company is unprofitable.
Forte Biosciences, Inc. (FBRX) had negative free cash flow of $72.0M in fiscal year 2025, likely due to heavy capital investments.
